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Multiple sclerosis (MS) is an autoimmune disease characterized by chronic inflammation 
in the central nervous system (CNS), which results in permanent neuronal damage and 
substantial disability in patients. Autoreactive T cells are important drivers of the disease; 
however, the efficacy of B cell depleting therapies uncovered an essential role for B cells 
in disease pathogenesis. They can contribute to inflammatory processes via presentation 
of autoantigen, secretion of pro-inflammatory cytokines, and production of pathogenic 
antibodies. Recently, B cell aggregates reminiscent of tertiary lymphoid organs (TLOs) 
were discovered in the meninges of MS patients, leading to the hypothesis that differ-
entiation and maturation of autopathogenic B and T cells may partly occur inside the 
CNS. Since these structures were associated with a more severe disease course, it 
is extremely important to gain insight into the mechanism of induction, their precise 
function, and clinical significance. Mechanistic studies in patients are limited. However, a 
few studies in the MS animal model experimental autoimmune encephalomyelitis (EAE) 
recapitulate TLO formation in the CNS and provide new insight into CNS TLO features, 
formation, and function. This review summarizes what we know so far about CNS TLOs 
in MS and what we have learned about them from EAE models. It also highlights the 
areas that are in need of further experimental work, as we are just beginning to under-
stand and evaluate the phenomenon of CNS TLOs.
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iNTRODUCTiON
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system (CNS). Based 
on the disease course, three different subtypes of MS are distinguished. The vast majority of patients 
exhibit a relapsing-remitting disease course (RRMS) at first. However, after a variable period of 
time (usually 10–15 years), RRMS patients experience progressive disability independent of relapses. 
Hence, this subtype is called secondary progressive MS (SPMS). Few patients (about 10%) experi-
ence a progressive disease course from the beginning [primary progressive MS (PPMS)] (1).
Demyelination, axonal damage, and neuronal loss as a result of immune cell infiltration are hall-
marks of the disease. A large body of evidence supports the concept of MS being a T cell-mediated 
autoimmune disease presumably directed against CNS antigens (2). However, it is not clear yet 
whether lesion formation requires additional immune mechanisms, such as antibody-mediated 
tissue destruction (3).
Intrathecal production of oligoclonal antibodies is a characteristic feature in MS patients (4). 
Moreover, plasma cells (PCs) accumulate in lesions and cerebrospinal fluid (CSF). Detection of 
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immunoglobulin G (IgG) and activated complement fragments 
and complexes in close proximity to actively demyelinating 
lesions indicates the involvement of antibody-mediated effector 
mechanisms. Technical progress over the last decade has helped 
to further characterize the humoral immune response in MS 
patients. Detection of extensive somatic hypermutation and a 
high frequency of clonally expanded memory B cells in MS 
lesions and CSF suggest that the observed B cell response is 
antigen-specific and not a random bystander effect (5).
However, recent clinical trials with a B cell depleting agent 
(anti-CD20 antibody) indicate that B cells are significant in the 
pathogenesis of MS beyond the production of antibodies (6). 
Anti-CD20 therapy rapidly reduces recurrence of relapses in 
MS patients, while antibody levels in the CSF remain essentially 
unaffected (7). B cells may also act as efficient antigen-presenting 
cells (APCs), especially in the context of cognate B cell:T cell 
interactions (8). Furthermore, the release of pro- (IL-6, LTα, 
TNFα, GM-CSF) and anti-inflammatory (IL-10, IL-35) cytokines 
by B cells may affect the immune response. Interestingly, analysis 
of B cells in MS patients suggests a preponderance of pro-inflam-
matory cytokines (9).
In this context, it was a significant finding that a relevant frac-
tion of SPMS patients show B cell-rich meningeal immune cell 
collections. These structures recapitulate lymphoid follicle-like 
features to some extent and, therefore, may provide an excellent 
microenvironment for the interaction of B and T cells (10, 11).
Initiation of adaptive immune responses as well as maintenance 
of immune homeostasis requires tightly regulated processes in 
our immune system. Secondary lymphoid organs (SLO) consti-
tute an important platform of this sophisticated system (12). The 
architecture of SLOs allows intense interactions between the dif-
ferent cellular components and, therefore, facilitates antigen pres-
entation to T and B cells. Encapsulated SLOs develop under the 
control of precise genetic programs at predefined key locations in 
the body during embryonic development and include the spleen 
and the lymph nodes. Those structures allow monitoring of self 
and foreign antigens displayed by APCs that survey tissues and 
traffic to SLOs. Lymphoid organs exhibit several typical features 
that allow the generation of a fast and efficacious anti-pathogen 
response. Germinal centers constitute one of them. These highly 
organized structures bring together antibody-secreting and 
proliferating B cells and follicular dendritic cells (FDCs) (13). 
Further characteristics are a T-cell zone populated by naïve 
T cells and central memory T cells recruited from the blood; high 
endothelial venules (HEV); and a network of stromal cells that 
provide chemokines and extracellular matrix (ECM) for cellular 
migration and structural integrity (14).
Inappropriate control of the immune system, for example, 
during autoimmunity, results in chronic inflammation. Under 
these circumstances, immune cells that infiltrate into peripheral 
tissues can shape highly organized follicle-like structures that 
share various features of SLOs. Accordingly, these ectopic 
lymphoid follicles are called tertiary lymphoid organs (TLOs) 
(12). Similarities include the presence of T and B compartmen-
talization, presence of APCs such as dendritic cells (DCs) and 
FDCs, stromal cells, HEV, and lymphatic vessels. However, in 
contrast to SLOs most TLOs lack a capsule. Moreover, TLOs 
are transient structures that often disintegrate upon clearance 
of the antigen.
Tertiary lymphoid organs have been observed in various forms 
of chronic inflammation, such as autoimmunity, chronic  graft 
rejections, persistent infection, artherosclerosis, and  cancer 
(12, 15–17).
Various factors of the local tissue microenvironment are 
involved in this process. Certain inflammatory mediators, such 
as members of the lymphotoxin (LT) family as well as different 
cytokines induce TLOs (18). Moreover, certain subsets of immune 
cells have been implicated in the development of TLOs (18). Even 
though their precise role is still elusive, it is assumed that they act 
as local sites of antigen presentation and lymphocyte activation, 
including somatic hypermutation and class switch recombination 
in B cells. Therefore, it stands to reason that they provide the ideal 
environment for antimicrobial responses, epitope spreading, as 
well as autoimmune exacerbation.
This review will discuss the occurrence and significance of 
TLOs in MS and its animal model experimental autoimmune 
encephalomyelitis (EAE).
OCCURReNCe AND SiGNiFiCANCe iN MS
Features/Characteristics of TLOs in MS
A morphological study in the late 1970s described accumulations 
of immune cells in chronic MS lesions (19). The authors found 
lymphocytes, macrophages, and PCs interacting with reticular 
cells in the perivascular space of parenchymal blood vessels (19). 
In addition, recent studies discovered distinct inflammatory infil-
trates around blood vessels of the leptomeninges of MS patients, 
in particular in SPMS patients at a late stage of the disease (10, 
11). Interestingly, a subsequent study on biopsy specimens found 
similar conglomerates of lymphocytes in the meninges of MS 
patients at a very early stage of the disease (20).
The degree of meningeal inflammation varied between 
analyzed samples. However, it was shown that an increased level 
of general perivascular and meningeal inflammation was accom-
panied by meningeal aggregates of CD20+ B cells, CD138+ and 
Ig+ PCs, and T cells buried in the sulci of the frontal, temporal, 
and parietal lobes, and in particular associated with the cingulate 
and precentral gyrus (10). Meningeal infiltrates exhibited various 
stages of organization, from elementary clusters of cells to highly 
organized follicle-like structures (10) (Figure 1). In line with this 
observation, some B cell aggregates featured a complex reticular 
network formed by CD35+ FDCs (10).
Interestingly, the degree of meningeal inflammation in the 
forebrain correlated with the degree of cerebellar meningeal 
inflammation (21). Yet, cerebellar meninges did not exhibit 
lymphoid-like aggregates as detected in the forebrain. One could 
argue that specific properties of the cerebellar subarachnoid 
space restrain the formation of such structures. Furthermore, 
analysis of cerebellar meninges revealed a high density of 
CD68+ macrophages, and the number of macrophages corre-
lated with parenchymal microglial activation, fitting well with 
earlier reports that described an association between meningeal 
cellular infiltrates and parenchymal microglial/macrophage 
activation (21, 22).
FiGURe 1 | Composition of CNS TLOs. TLOs in the CNS show different degrees of organization ranging from immature loose B cell aggregates (left) to highly 
organized lymphoid structures (right). Notably, at any time, only a minor fraction of cellular aggregates shows the highest degree of organization, however, the 
frequency of highly organized TLOs increases over time after onset of disease. Immature loose B cell aggregates show clustering of B cells in the meninges often in 
proximity to a meningeal blood vessel, scattered T cells, and a few reticulin fibers (left panel). In contrast, highly organized TLOs (right panel) are characterized by 
large B cell clusters next to a more or less defined T cell zone, and a dense network of reticulin fibers decorated with extracellular matrix (ECM) and chemokines. 
Reticulin fibers are produced by meningeal stromal cells that have differentiated into FRC-like cells. Sometimes FDCs can be detected at the center of the B cell 
follicle, which may have differentiated from pericytes. Plasma cells and antibodies are found in proximity to highly organized TLOs. In addition, HEVs can be detected 
in some highly organized TLOs, which may regulate infiltration of lymphocytes into the TLO.
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Many B cells within follicles stained positive for the prolif-
eration marker Ki67 (10). B cell aggregates with well-developed 
FDC networks showed clusters of Ki67+ nuclei suggesting 
formation of germinal centers. However, these follicles lack an 
interfollicular T cell zone with HEV as it was observed in ectopic 
lymphoid tissue in other organs.
In conflict to these data, a recent report studying a different 
cohort of patients did not detect any follicle-like structures in the 
meninges of MS patients (23).
In summary, these observations suggest that some MS patients 
exhibit strong meningeal inflammation with formation of well-
organized follicles. These intrameningeal structures feature some 
characteristics reminiscent of TLOs as they have been described 
in other persistently inflamed organs. Discrepancies in regard 
to the detection of these aggregates may be based on biological 
heterogeneity across patients. Furthermore, it is not clear whether 
these immune cell infiltrates persist for longer periods or whether 
they are only transiently present during periods of more active 
CNS inflammation. Technical difficulties may also contribute 
to this inconsistency as these structures tend to be very small 
(<100 μm in thickness), and meninges easily detach at autopsy. 
Therefore, these follicle-like structures may get lost during tissue 
processing. One challenge might be to provide guidelines on how 
to handle the tissue and to define criteria that allow the reproduc-
ible identification of these structures.
induction/Formation of TLOs in MS
As only a fraction of MS patients shows B cell follicles in the 
meninges, ectopic lymphoid neogenesis must be controlled by 
a specific set of inflammatory signals. Likewise, it is known 
that some tissues and tumors are more prone to the devel-
opment of TLOs than others indicating an important role 
of the microenvironment. The CNS holds a special status as 
several barriers, including the blood–brain barrier (BBB), the 
blood–meningeal barrier and the blood–CSF barrier control 
passage of macromolecules and immune cell infiltration (24). 
However, the CNS is rather an immune-specialized than an 
immune-privileged site, as it is controlled by extensive immune 
surveillance under physiologic conditions (24). Moreover, recent 
reports have described a functional lymphatic system in the 
CNS draining macromolecules and cells to deep cervical lymph 
nodes (cLN) (25, 26).
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The question is what factors induce the formation of ectopic 
lymphoid follicles in this special environment. It is assumed that 
the formation of TLOs mimics significant steps of the organo-
genesis of SLOs. Initiation of SLOs is characterized by a close and 
reciprocal interaction of hematopoietic CD4+CD45+CD3− lym-
phoid tissue inducer (LTi) cells and lymphoid tissue organizer 
(LTo) cells of mesenchymal origin. The lymphoid chemokine 
CXCL13 released by LTo cells plays a crucial role as it attracts 
CXCR5-expressing LTi cells (12). CXCL13 is elevated in CSF and 
active lesions of MS patients and intrathecal Ig and occurrence 
of B cells and plasmablasts correlates with CXCL13 levels in the 
CSF (27–30). Furthermore, about 20% of CSF CD4+ T cells and 
almost all B cells express CXCR5 suggesting that CXCL13 serves 
as an important chemoattractant to the CNS compartment (27). 
Moreover, FDCs in meningeal lymphoid aggregates express 
CXCL13 further indicating an important role for this chemokine 
in TLO formation (10).
Interestingly, untreated MS patients show elevated numbers 
of innate lymphoid cells in the peripheral blood and CSF 
(31,  32), and a recent study detected retinoic acid receptor-
related orphan receptor γt (RORγt)-positive and CD3-negative 
cells in submeningeal B cell follicles (33). These cells may 
represent group 3 innate lymphoid cells, which comprise the 
LTi cell subset, and thus could potentially be involved in TLO 
formation.
In addition, there is evidence that, besides LTis, certain 
immune cell subsets in inflammatory lesions can trigger the 
development of TLOs. In particular, IL-17-secreting CD4 
T helper (Th17) cells have been implicated in the pathogenesis 
of TLOs, and MS patients show an increased frequency of Th17 
cells in peripheral blood and CSF compared with controls 
(34–36). Th17 cells secrete a variety of cytokines, among others 
IL-17, IL-21, and IL-22 (37). Interestingly, all of them have been 
linked to the formation of lymphoid follicles (18). As IL-17 was 
shown to induce CXCL13 (38), this might be an additional, 
indirect mechanism how Th17 cells contribute to the formation 
of TLOs.
In this context, it is interesting that there might be an ancestral 
link between adult LTi cells and Th17 cells (39, 40). Indeed, LTi 
cells and Th17 cells share several features as both cells express the 
transcriptional regulator RORγt; can respond to IL-23 and aryl 
hydrocarbon receptor ligands; and can produce IL-17, IL-22, and 
GM-CSF (41).
These factors and probably others like BAFF (B lymphocyte 
stimulator) and LT might contribute to create a permissive 
microenvironment for accumulation of B cells during chronic 
inflammatory conditions.
Function of TLOs in MS
Upon antigen encounter, naïve B lymphocytes develop into plas-
mablasts and undergo further maturation, e.g., hypermutation 
in germinal centers. TLOs, besides SLOs, are known to provide 
excellent niches where specific plasmablasts can further differen-
tiate into PCs (12).
Detection of intrathecal Ig synthesis and oligoclonal bands 
(OCB) are typical features in MS patients. Ig synthesis occurs 
early in the course of the disease, and once acquired, persists 
unchanged throughout the disease in the majority of cases. 
Therefore, it serves as an important supportive diagnostic crite-
rion (42).
Multiple sclerosis lesions often show deposition of antibod-
ies and activated complement bound to disintegrating myelin 
(43, 44). Interestingly, the antibody repertoire in the CSF reflects 
Ig transcripts of B cells populating both CSF and brain lesions 
(45). Clonally related, antigen-experienced B cells are found in 
the CSF and peripheral blood as well as in the meninges and 
the parenchyma of MS patients suggesting an active immune 
axis between these different compartments (45–47). However, 
it remains unclear where these B cells encounter antigen and 
mature further. A recent study analyzed paired tissues comprising 
cLN and CNS by deep sequencing. Founding members of clonal 
families were primarily detected in cLNs, while more mature 
members of these founders were found both in the cLNs and the 
CNS (48). These data provide further evidence that B cells can 
overcome tissue barriers between the periphery and the CNS. 
However, they also suggest that while the first antigen contact 
occurs in the periphery further maturation can happen both in 
the periphery and the CNS.
Meningeal immune cell aggregates recapitulate lymphoid 
follicle-like features to some extent and, therefore, may provide 
an excellent microenvironment for the interaction of B cells with 
T cells and FDC. Accordingly, they might support local B and 
T cell activation and further maturation. Therefore, one could 
speculate that antigen-experienced and clonally expanded B cells 
arise from these structures.
Overall, the above-mentioned studies suggest a role of 
meningeal TLOs in humoral- and cell-mediated immunity in 
MS patients.
Clinical Relevance of TLOs in MS
It is still not clear whether meningeal TLOs have a pathophysi-
ological significance in MS or just represent an epiphenom-
enon. A recent postmortem study of chronic MS patients 
revealed extensive cortical demyelination affecting about 25% 
of the cerebral cortex in contrast to 5% of the subcortical/
periventricular white matter (WM) (49). Similar observations 
were made in the cerebellum where demyelination of gray mat-
ter (GM) was far more pronounced than WM pathology (WM 
3% versus GM 14%, representing % area of lesion in relation 
to total area) (21). Recently, MRI studies further broadened 
our knowledge about the prevalence of cortical lesions in vari-
ous subtypes of MS and at different stages of the disease (50). 
Cortical lesions are clearly linked to cognitive impairment and 
disability progression (51). In this context, it is interesting that 
several studies suggested a correlation between the occurrence 
of meningeal inflammation and cortical demyelination (11, 
20–22, 52, 53). Notably, formation of follicle-like structures 
in a fraction of SPMS cases was accompanied by increased 
meningeal inflammation and was associated with pronounced 
subpial cortical pathology. Concurrently, follicle positive cases 
showed a more severe disease course with younger age at 
disease onset, younger age at irreversible disability, and earlier 
death (11, 22). In addition, a study analyzing cortical biopsy 
specimens of early-stage MS patients also revealed a strong 
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topographic association of moderate-to-marked meningeal 
inflammation with cortical demyelination (20). However, 
these findings are still a matter of debate and need validation 
in larger cohorts, especially since another study did not find 
evidence for an association of meningeal inflammation and 
cortical lesions in chronic MS (23).
Further histological analysis of follicle positive SPMS cases 
revealed a significant reduction in the thickness of the cortical 
GM layers in the precentral, frontal, and temporal gyrus (52). 
In line with this observation, these cases exhibited a substantial 
loss of neurons, which also included neurons with a pyramidal 
morphology. Interestingly, these pathologic changes exhibited a 
clear pial to WM gradient in the precentral gyrus, both in GM 
lesions and normal appearing GM (52). Overall, these observa-
tions strengthen the hypothesis that the meningeal inflamma-
tory milieu is involved in the pathogenesis of cortical damage 
in a substantial number of SPMS cases. CD8+ T cell-mediated 
immunopathology could be a potential cause as follicles harbor 
a considerable number of CD8+ T cells (54). Both direct mecha-
nisms via cytotoxic tissue damage and indirect mechanisms, e.g., 
by inducing activation of microglia might play a role. Other pos-
sible triggers are soluble factors released by inflammatory cells 
in the meninges. Finally, it could also be an antibody-mediated 
process, as an association between intrathecal immunoglobulin 
levels and cortical lesion load in patients with clinically isolated 
syndrome has been reported (55).
A striking difference between WM and GM damage is the 
lack of inflammatory cell infiltrates and rare deposition of 
immunoglobulin in cortical lesion (56–58). However, experi-
mental models have shown that the GM does not support the 
persistence of inflammatory cells over extended periods of 
time (58). Thus, lack of inflammatory cells in GM with axonal 
damage or neuronal loss does not necessarily mean that these 
pathologic changes are not due to prior inflammatory events. 
However, an alternative hypothesis is that neurodegenerative 
processes unfold independently of inflammation and contribute 
to the attrition of GM structures in longstanding MS cases (59). 
Yet, axonal damage and neuronal loss in GM structures may 
also be a consequence of distant underlying WM lesions, e.g., 
via Wallerian degeneration. However, there was no correlation 
between the number of subpial GM lesions and WM lesions sug-
gesting that inflammatory meningeal lesions actually determine 
GM damage (52).
Eventually, beyond further analysis of tissue samples from 
MS patients or autopsy tissue, advanced imaging technolo-
gies will contribute to solving these questions. In particular, 
development of MRI techniques that resolve meningeal 
inflammatory lesions and enable the unequivocal visualization 
of cortical lesions are sorely needed to analyze these issues in 
living patients.
Overall, the clinical relevance of meningeal TLOs in MS 
patients remains elusive. Validity of studies in human samples is 
limited as most of the tissues available are collected at a late stage 
of the disease. Poor quality of tissue, i.e., due to a long postmortem 
interval, might be another handicap. Thus, in order to further our 
understanding of CNS TLO formation, function, and impact, we 
can make use of the animal model for MS, EAE.
OCCURReNCe AND SiGNiFiCANCe  
iN eAe
Experimental autoimmune encephalomyelitis has been employed 
for decades to study cellular and molecular pathogenic mecha-
nisms that may also be relevant for MS pathogenesis and, in 
fact, many important mechanistic insights as well as successful 
therapeutic approaches have emerged from EAE studies. Thus, the 
EAE model was instrumental in demonstrating the importance of 
myelin-reactive CD4 T helper cells as disease drivers, as disease 
can be induced in healthy animals solely by transfer of these cells 
(60). Furthermore, the encephalitogenic properties of different 
T helper cell subsets were defined in numerous EAE studies, 
starting in the 1990s when IFN-γ-producing Th1 clones were 
described to be pathogenic while Th2 cells were characterized as 
non-pathogenic in the context of autoimmune CNS inflammation 
(61–64). When Tregs and Th17 cells entered the stage these stud-
ies were revisited and extended to show that both Th1 and Th17 
cells can induce EAE, whereas Tregs aim to control the inflamma-
tory processes (65). Since the majority of research efforts in the 
EAE field focused on T helper cells, the efficacy of B cell depleting 
therapies in MS came as quite a surprise for EAE researchers and 
raised the question why the obviously pathogenic role of B cells in 
the disease process was not recognized earlier in the EAE model. 
Rather than neglect and ignorance of the investigators, the most 
important reason lies in the experimental details of the model 
itself: the majority of EAE studies use immunization with myelin 
peptides together with adjuvant to induce disease. Since the self-
peptide is already provided and, in this form, will most efficiently 
be taken up and presented by DCs, a potential role of B cells in 
processing/presentation of self-antigen and thereby activation of 
self-reactive T cells is largely bypassed in peptide immunization 
models. As a prominent example, it was shown that develop-
ment of disease in C57Bl/6 mice immunized with MOG35–55 in 
CFA – the most widely used EAE model – is B cell independent 
and features very limited humoral responses (66,  67), whereas 
immunization of C57Bl/6 mice with recombinant human MOG 
protein relies on B cells to process and present the antigen and 
initiate the pathogenic cascade (66, 68, 69). Hence, moving away 
from the EAE blockbuster model, one can find several different 
EAE models in the literature that involve strong pathogenic (and 
also regulatory) B cell responses. Besides studying the role of B 
cells as antibody sources, APCs, and cytokine producers, a few 
studies have also described B cells to participate in TLOs in the 
CNS of EAE mice:
•	 After description of TLOs in MS brain, TLOs in EAE were 
first searched for and identified with relatively low frequency 
in SJL mice immunized with proteolipid protein (PLP)139–151 
– the only model, where TLOs develop after immunization 
with peptide (70, 71). In contrast, there is no robust evidence 
for TLO formation in the classical C57Bl/6-MOG35–55 immu-
nization model. One reason for this difference may lie in the 
genetic background, since in the RRMS of the SJL background 
TLOs have more time to develop than in the relatively short 
acute–chronic disease course following immunization of 
C57Bl/6 mice with MOG35–55.
FiGURe 2 | Location of CNS TLOs. Sagittal view of the mouse brain (left) and horizontal view of the spinal cord (right) show preferential location of CNS TLOs (red 
stars) in association with the meninges.
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•	 TLOs have also been described in C57Bl/6 mice immunized 
with a MBP–PLP fusion protein (MP4). In this model, mice 
develop a B cell-dependent chronic EAE that can be observed 
for up to 60 days post immunization (72).
•	 In the opticospinal EAE (OSE)-mouse, which features both a 
transgenic MOG-specific TCR as well as a MOG-specific BCR 
and spontaneously develops EAE, TLO-like structures were 
found in the CNS (73, 74).
•	 Following adoptive transfer of either MOG-specific Th17 cells 
in the C57Bl/6 background or PLP-specific Th17 cells in the 
SJL background, TLOs were identified with relatively high 
frequency in the CNS of sick mice (75, 76).
The fact that TLOs have been detected in several models that 
differ in regard to genetic background, identity and form of anti-
gen, and method of disease induction implies that TLO formation 
is not just an exotic epiphenomenon, but will occur under varying 
conditions. However, characterization of EAE TLOs yielded very 
heterogeneous results not only between different models but 
also within the same model, suggesting that TLO development 
and regulation is very complex. Below, we are summarizing the 
results from different models regarding location, structural and 
cellular composition, induction, function, and clinical relevance 
of EAE TLOs to evaluate whether general principles important 
for CNS TLO formation can be identified, which could then also 
be applicable for MS TLOs.
TLO Location and Composition in eAe
Across the different EAE models and in agreement with the 
data from MS studies (see Features/Characteristics of TLOs in 
MS), TLOs are consistently found in association with meninges 
(Figure 2). Thus, both in the SJL immunization model as well as 
after transfer of Th17 cells on the SJL background, TLOs form pri-
marily in the brain meninges, particularly those lining brainstem 
and ventricles (70, 71, 76). Similarly, in the MP4 immunization 
model TLOs form in the cerebral periventricular space, but 
also in the cerebellum and in association with spinal meninges 
(72). Upon transfer of Th17 cells in the C57Bl/6 background 
the majority of TLOs are located in the spinal meninges (75), 
and in the spontaneous OSE model TLOs are exclusively found 
in the spinal meninges (74). Whether TLOs form in the brain 
or spinal cord is most likely a consequence of the main route 
of infiltration, which differs between models. Thus, it has been 
shown that in the OSE model inflammation is restricted to optic 
nerve and spinal cord (73, 77). In addition, it is known that Th17 
cells promote brain inflammation (78). However, whether in the 
brain or in the spinal cord, it is clear that TLOs preferentially 
form in association with meninges. This may be partly due to 
the high density of vessels in the meninges compared with the 
parenchyma, which have been shown to be an important point 
of entry for infiltrating leukocytes (79, 80). HEV, which express 
adhesion molecules like PNAd or MadCAM to specifically 
attract naïve lymphocytes into SLOs and which have also been 
described in TLOs in other organs, were detected within TLOs 
in the MP4-immunization model (72). However, no evidence for 
HEVs was found in the spontaneous OSE model nor in the Th17 
transfer model (C57Bl/6 background) (74, 75), while presence of 
HEVs was not determined in the SJL immunization and SJL Th17 
transfer models. Since HEVs develop in response to cytokines 
like LT, their formation may require some time and occur only 
in the most mature TLOs. In addition, it is also possible that due 
to the abundance of meningeal vessels, which become permeable 
during CNS inflammation due to break-down of the BBB, the 
development of HEVs is not absolutely required for the recruit-
ment of lymphocytes into CNS TLOs. In contrast, for example, 
tumor TLOs may be much more dependent on proper develop-
ment of HEVs since the tumor environment is comparatively 
poorly vascularized.
Another important reason for the preferred formation of TLOs 
in association with meninges is the structural support that can be 
provided by the meningeal stromal cells. SLOs are structurally 
organized by fibroblastic reticular cells (FRCs), which line the 
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subcapsular sinus and the conduits for antigen transport into 
the T cell zone, and secrete ECM components to form a dense 
network of reticulin fibers along which T cells, APCs, and B cells 
can migrate to their designated areas. FRCs are also an important 
source of the chemokines that retain T cells (CCL19 and CCL21) 
and B cells (CXCL13) in the SLO and organize it into separate 
B cell and T cell zones. In EAE TLOs, reticulin fibers suggestive 
of stromal FRC-like cells were described in several models, 
including the MP4-immunization model, the spontaneous OSE 
model, and the Th17 transfer model (C57Bl/6) (72, 73, 75). In a 
more detailed analysis, Pikor and colleagues could show that the 
fraction of FRC-like meningeal fibroblasts, which express Pdpn, 
PDGFRα, PDGFRβ, and Cadherin11 on their surface and secrete 
ECM components including fibronectin and ERTR7, increases 
during CNS inflammation (76). Therefore, the relative abundance 
of fibroblasts in the meninges, which can be stimulated to adopt 
FRC-like phenotype and function, may partly explain why TLOs 
are predominantly located in the meninges.
The other structurally essential stromal cell in the SLO is 
the FDC, which is positioned in the B cell follicles, where it 
presents opsonized antigen to induce affinity maturation of 
B cells and produces a network of reticulin fibers organizing 
migration into and structure of the follicle. In addition, FDCs 
are the main source of the B cell attracting chemokine CXCL13 
in SLOs. Data from the different EAE models are heterogeneous 
in regard to the presence of FDCs in CNS TLOs. FDCs could 
not be identified in the spontaneous OSE model, nor in the 
Th17-transfer models (both C57Bl/6 and SJL), whereas FDCs 
were detected via the complement receptor CD35 or the marker 
FDC-M1 in the SJL- and the MP4-immunization model (71, 
72). Like FRCs, FDCs are of stromal origin, and it has been 
suggested that they appear in TLOs as a consequence of dif-
ferentiation/maturation of ubiquitous local precursors, namely 
PDGFRβ+ pericytes (81), rather than migrating from SLOs. 
This maturation process requires the proper cytokine signals 
(primarily LT, TNF and potentially also others) and it may also 
take some time. Consistent with this idea, FDC-positive TLOs 
were observed late in the disease course, either upon relapses 
in the SJL-immunization model or in the chronic phase of EAE 
30–57 days post onset in the MP4-immunization model (71, 72). 
Thus, absence of FDCs in the spontaneous OSE model and Th17 
transfer models might be caused by lack of appropriate FDC 
maturation signals or by lack of time leading to an incomplete 
differentiation process. The latter may be especially true for the 
Th17 transfer models, where mice were analyzed comparatively 
early (5–20 days post onset) to prevent extended suffering due 
to severity of disease (75, 76). On the other hand, it is also 
unclear whether FDCs are required for antigen presentation in 
germinal center reactions in TLOs. Though presence of FDCs 
has been demonstrated in TLOs in other organs, it remains to be 
formally shown that they are required for antigen presentation. 
Thus, it is possible that other APCs can substitute for FDCs 
in CNS TLOs. Considering that meningeal macrophages have 
been shown to present antigen and reactivate infiltrating T cells 
during EAE (79, 80, 82, 83) and that they can be easily detected 
scattered in and around CNS TLOs they are certainly a good 
candidate.
Aside from structural components, segregated T and B cell 
zones are of course a hallmark characteristic for SLOs and TLOs. 
Across all EAE models, aggregation of B cells was considered a 
defining criterion for CNS TLOs. In contrast, T cells seemed to 
be scattered rather than clustered and were detected around and 
sporadically within the B cell zones (Figure 1). Their presence on 
the border or within the B cell zone may be a consequence of T cells 
acting as follicular T helper cells (TFH) to support the B cell mat-
uration process (see TLO Function in EAE). Furthermore, the 
chemokines responsible for formation of a separate T cell zone 
(mainly CCL19 and CCL21) may not be so strongly expressed 
in the CNS, in contrast to the B cell zone-organizing chemokine 
CXCL13, which has been detected in several of the EAE models 
(see Induction/Formation of TLOs in EAE). Given that reactiva-
tion of T cells in the CNS and especially in the meninges has been 
clearly demonstrated also in the absence of TLOs (79, 80, 82, 83), 
T cells may also be less dependent on structure and clustering for 
their reactivation than B cells.
induction/Formation of TLOs in eAe
For the formation of SLOs both LTo and LTi are required. During 
normal lymph node development, LTis (CD4+CD3−RORγt+ 
IL7Rα+) stimulate stromal cells to differentiate into LTos, which 
in turn start producing fibers and conduits and expressing adhe-
sion molecules and chemokines that organize the SLO and guide 
lymphocytes to their designated areas. This stimulation of LTos by 
LTis is mediated primarily via cytokines of the TNF superfamily, 
especially LT. The heterotrimer LTα1β2 expressed on the LTi cell 
surface engages with LTβ receptors on stromal cells to initiate the 
differentiation process. Additionally, LTis also secrete cytokines, 
including LTα3, and TNFα which further activate LTos. In TLO 
formation, other cell types including type 3 innate lymphoid 
cells and T cells can perform the tasks of LTi, as long as they can 
provide the proper cytokine signals (84). Which cell type initi-
ates the TLO formation process in the CNS was not investigated 
in detail in the immunization models nor in the spontaneous 
OSE model. However, increased expression of LT was detected 
in the SJL-immunization model at onset and upon relapses, and 
neutralization of LT prevented relapses and decreased expres-
sion of the B cell attracting chemokine CXCL13 in the CNS (71). 
These data suggested that LT-signaling is involved in activating 
LTos in the CNS, but did not identify the cellular source of LT. 
The Th17 adoptive transfer model (C57Bl/6) demonstrated that 
Th17 cells themselves are the cellular initiators for CNS TLO 
formation, since TLO formation was not observed after transfer 
of other T cell subsets, including Th1 cells, despite development 
of clinical disease (75, 85). Interestingly, Th17 cells and classi-
cal LTi share expression of several markers, including RORγt, 
IL-17, IL-22, CCR6, and IL-7Rα, and thus Th17 cells may also 
be able to function as LTi in stimulating CNS fibroblasts to act 
as LTo. This hypothesis was investigated in detail in the SJL Th17 
adoptive transfer model (76): Pikor and colleagues could show 
that IL-17 and IL-22 together act on meningeal FRCs to induce 
remodeling of actin and collagen and production of ECM com-
ponents, which ultimately leads to formation of fibrous networks 
providing proper structure for the TLO. Interestingly, IL-17 and 
IL-22 also induced expression of IL-6 and IL-23 in FRCs, which 
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in turn supported de novo Th17 differentiation in the CNS, and 
may be a mechanism to ensure stable supply of Th17 cytokines 
for the FRCs to maintain their differentiation status. While FRC 
remodeling was independent of LT-signaling, production of 
CXCL13 by meningeal FRCs and therefore accumulation of B 
cells and deposition of complement in the lesion required intact 
LT-signaling. Together, these data suggest that the combina-
tion of LT and the Th17 cytokines IL-17 and IL-22 efficiently 
stimulates the meningeal fibroblasts to differentiate into FRCs 
(and potentially FDCs) and act as LTo in CNS TLOs. This also 
explains why there is almost no TLO formation in recipients of 
pure Th1 cells (75): although Th1 cells produce LT and TNFα and 
thus may even activate the meningeal fibroblast and stimulate 
them to produce CXCL13, complete maturation into FRCs (and 
potentially FDCs) additionally requires the presence of the Th17 
cytokines IL-17 and IL-22. Importantly, both IL-17 and IL-22 
have also been implicated in TLO formation in other organs/dis-
ease models including during iBALT formation in the lung (38), 
lymphoid follicle formation in the intestine during Citrobacter 
infection (86), and virus-induced TLO formation in salivary 
glands (87).
Data regarding the impact and requirement of chemokines 
for CNS TLO formation in EAE are limited. As already men-
tioned, CXCL13 is produced primarily by FDCs in SLOs to 
attract CXCR5-expressing B cells and TFH cells into the follicles 
and form a separate B cell zone. In all EAE models except the 
OSE model elevated CXCL13 mRNA levels were reported, and 
in some cases CXCL13 protein was also detected by immuno-
histochemistry at least in the more mature TLOs. CXCL13 was 
detected even in the absence of FDCs suggesting that in the 
CNS other cells can be a significant source of this chemokine. 
In fact, Pikor and colleagues showed that meningeal FRCs can 
produce CXCL13 in response to LT (76), and a recent study 
demonstrates that FRCs can also produce CXCL13 in response 
to IL-22 (87). While the evidence for presence of CXCL13 in 
CNS TLOs is comparatively robust, evidence that CXCL13 
actually causes the attraction and aggregation of B cells into 
CNS TLOs is still missing. Another chemokine that may play 
a role in CNS TLO formation is CXCL12, which interacts with 
CXCR4+ B cells. Intriguingly, Fleige and colleagues have shown 
that IL-17 can induce CXCL12 expression in stromal cells lead-
ing to FDC-independent TLO formation in the lung during P. 
aeruginosa infection (88), and another study showed that IL-22 
can upregulate CXCL12 expression in epithelial cells (87). Given 
the importance of Th17 cells for CNS TLO formation in EAE, 
it is plausible that CXCL12 may contribute to B cell attraction 
and aggregation. While CXCL12 has been detected in standard 
EAE models, where it was suggested to retain infiltrating cells 
in the perivascular compartment (89), presence/relevance of 
CXCL12 was not tested in any of the TLO EAE models. The role 
of T cell chemokines for formation of CNS TLOs in EAE is even 
less understood. In SLOs, FRCs produce CCL19 and CCL21 to 
guide CCR7-positive T cells into the T cell zone. Constitutive 
expression of CCL19 has been detected in healthy CNS and 
increased levels of CCL19 and CCL21 were detected in the 
CNS in regular EAE and MS (90–92). The SJL Th17 adoptive 
transfer model showed a slight LT-independent upregulation of 
CCL21 in meningeal FRCs (76), but it remains to be determined 
whether this is relevant for CNS TLO formation. Taken together, 
the data suggest that CCL19/CCL21 produced by meningeal 
FRCs may recruit T cells into CNS TLOs in EAE. However, as 
mentioned already above, the fact that T cells seem to be much 
more scattered than B cells in CNS TLOs questions the pres-
ence and also the need for strong T cell chemokine signals that 
establish formation of a separate T cell zone. In summary, much 
more functional experimental work is needed to clearly define 
the role of chemokines in CNS TLO formation.
TLO Function in eAe
As for SLOs, the functions of a fully developed TLO comprise 
priming of naïve lymphocytes to new locally derived antigen 
resulting in differentiated antigen-specific T effector cells and 
B  cells that underwent germinal center reactions yielding 
affinity-matured B memory cells and antibody-producing PCs. 
Studies in the MP4-immunization model, the spontaneous OSE 
model, and the SJL Th17 adoptive transfer model revealed T cell 
proliferation in TLOs (72, 74, 76). However, since T cells can also 
proliferate in the CNS in the absence of TLOs these data alone 
do not prove functionality of CNS TLOs. Additional evidence is 
provided in the MP4-immunization model, since T cells isolated 
from the CNS showed specificity not only for the immunizing 
antigen MP4 but also for the CNS-specific antigen MOG (72), 
suggesting that those MOG-specific T cells may have been 
primed directly in CNS TLOs. Although one cannot completely 
exclude the possibility that these MOG-specific T cells were 
primed in the periphery, the fact that MOG-specific T cells could 
not easily be detected in SLOs points toward T cell priming in the 
CNS. Similarly, in the SJL Th17 adoptive transfer model it was 
shown that in order to detect endogenous T cells differentiated 
into Th17 effector cells in the CNS, transferred T cells needed to 
express LT, which in turn stimulated meningeal FRC remodeling 
and expression of Th17 differentiation cytokines (76). These 
data – though not definite evidence – still support the idea 
that priming and differentiation of naïve T  cells in response 
to CNS antigen may happen in CNS TLOs; however, more 
experimental evidence is needed to confirm this hypothesis. 
In  regard to germinal center reactions, it was demonstrated 
in the C57Bl/6 Th17 adoptive transfer model that transferred 
Th17 cells in the CNS expressed markers associated with TFH 
cells including CXCR5 and Bcl6, as well as GC markers like 
GL7 and PNA (75). Thus, Th17 cells may function as TFH cells 
in CNS TLOs and provide help to B cells in GC reactions. In 
line with this, Th17 cells were shown previously to be excellent 
B cell helpers (93), and thus, the plasticity of Th17 cells to 
adopt TFH functions may be another reason why Th17 cells are 
superior to other T cell subsets in supporting TLO formation. 
Accordingly, some but not all CNS B cells also expressed GC 
markers including GL7, PNA, and Bcl6, some had undergone 
class switch recombination to IgG, and a few PCs were detectable 
in the CNS of Th17 recipients (75). Proliferating B cells were also 
found in the SJL and MP4-immunization model (70–72), and 
some B cells in the MP4-immunization model also expressed 
GC markers and AICD, the enzyme required for CSR and 
somatic hypermutation (72, 94). Consistent with this finding a 
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germline transcript analysis indicated that B cells switched to 
IgG2b and IgG3 in the CNS, and sequencing of Ig transcripts 
revealed some CNS B cell clones that could not be detected in 
the spleen (94). Although these data support the hypothesis that 
GC reactions may happen in CNS TLOs, one has to keep in 
mind that it is extremely difficult to exclude that lymphocytes 
acquired the observed phenotype in the periphery and then 
migrated to the CNS. In contrast to these data, CNS B cells 
in the spontaneous OSE model showed no GC phenotype nor 
isotype switch, but appeared to be rather activated naïve B cells 
(74), confirming the notion that across the different models 
CNS TLOs are quite heterogeneous in their stage of develop-
ment (Figure  1). Together the data from the different models 
suggest that definitely not all, but maybe the most organized 
and mature TLOs are also functional in supporting generation 
of differentiated T effector cells and affinity-matured B cells 
specific to CNS antigens.
Clinical Relevance of TLOs in eAe
Although CNS TLOs have been detected in several EAE mod-
els, their impact on the clinical disease course is completely 
unclear. Based on data from MS patients, where occurrence 
of TLOs was associated with a more aggressive disease course 
(10, 11), it has been postulated that TLOs in the CNS support 
differentiation and maturation of CNS antigen-specific effector 
lymphocytes, which continuously fuel the inflammatory process 
and thereby drive disease progression and chronicity. Except for 
the spontaneous OSE model, where TLO frequency and size was 
associated with a chronic and more severe disease course (74), 
presence of TLOs did not clearly correlate with disease severity 
in any of the other TLO EAE models. This may be explained by 
TLO frequency and kinetics of TLO development: In the SJL 
and MP4-immunization models TLO frequency increases in 
the late phases of disease, i.e., upon relapses or in the chronic 
phase of EAE 30–57 days post onset (71, 72). Although these 
late time points allow the TLOs to become comparatively 
mature and organized, the overall TLO frequency may still be 
too low (around 10 TLOs per mouse) to have a clinically vis-
ible effect. On the other hand, TLO frequency is significantly 
higher in the Th17 adoptive transfer models (around 60 TLOs 
per mouse) than in immunization models; however, mice were 
analyzed relatively early (2–15 days post onset) and thus TLOs 
may not yet be developed enough (reflected by lack of FDCs 
and HEVs) to affect the disease course (75, 76). In addition, 
the disease severity in Th17 adoptive transfer EAE is generally 
very pronounced and mice often show no recovery possibly due 
to irreversible tissue damage, making it very difficult to detect 
an exacerbation of clinical signs, especially using the rough 
scoring system common in the EAE field. Although it is likely, 
that CNS TLOs worsen clinical disease, especially considering 
that in the SJL Th17 adoptive transfer model TLOs promoted 
differentiation of endogenous Th17 effector cells (76), there is 
also the possibility that CNS TLOs counteract inflammation 
by generating regulatory T and B cells. This phenomenon has 
been observed in TLOs in the tumor microenvironment, but 
has never been investigated in CNS TLOs in EAE. A correlation 
of TLOs with cortical pathology, as described in MS brain (see 
Clinical relevance of TLOs in MS), has so far not been detected 
in TLO EAE models. Considering that cortical pathology may 
be caused by soluble and/or cellular factors emerging from 
meningeal TLOs over time, lack of cortical pathology in EAE 
may be a consequence of the short disease course when com-
pared to human MS. On the other hand, it is also possible that 
this pathologic aspect of MS is simply not well recapitulated in 
EAE, since important cues (for example, presence and action of 
CD8 T cells) may be different in EAE and MS.
In order to define the clinical relevance of TLOs, an EAE model 
with reasonable frequency of TLOs and relatively mild disease 
course, which can be observed for long time periods, would be 
ideal. In addition, experimental methods need to be developed, 
which inhibit TLO formation in the CNS without disturbing 
the regular immune responses happening in the CNS and in the 
periphery during EAE. Thereby, one could gain detailed insight 
into the clinical relevance of TLOs in EAE.
CONCLUDiNG ReMARKS
In summary, data from the last decade have revealed the exist-
ence of TLOs in the CNS of MS patients, and TLO formation 
can also be recapitulated in the MS animal model EAE, which 
will enable us to study the mechanisms of TLO formation as well 
as their precise functions and impact on disease development 
in more detail in the future. In general, the existence of TLOs 
further support an important role of B cells in MS pathogenesis, 
but the data also show a wide spectrum of TLO developmental 
stages ranging from simple B cell aggregates to highly organized 
structures (Figure 1), suggesting that a complex network of cel-
lular players and cytokine signals is required to build these struc-
tures. Although some contributing factors and mechanisms like 
involvement of Th17 cells have now been exposed, considerable 
experimental work is needed to understand the phenomenon 
of CNS TLOs. The hypothesis that CNS TLOs support differen-
tiation and maturation of CNS antigen-specific T and B effector 
cells, and thereby propagate continuous inflammation directly in 
the CNS – although attractive – remains to be first tested experi-
mentally, and only then one can start thinking about CNS TLOs 
as therapeutic targets.
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